Pangenomic expands Nara.Care with DNA program launch

Executive Summary

• Pangenomic Health Inc. has launched a DNA testing program integrated into its Nara.Care AI platform, marking a significant expansion of its personalized wellness offerings.
• The company has partnered with a leading DNA testing technology developer to market "Agenta" branded DNA testing kits to health-conscious consumers in Canada, with plans to expand into the United States in early 2026.
• The initiative aims to leverage genetic data to provide actionable insights via AI models regarding diet, fitness, metabolism, and brain function, while implementing safeguards for genomic data privacy.

Key Details

• Product Launch: Introduction of Agenta branded DNA testing kits as part of the Nara.Care artificial intelligence platform.
• Target Market: Initial rollout targets health-conscious consumers in Canada; expansion into the United States is planned for early 2026.
• Technology Integration: The DNA tests feed data into the Nara.Care AI platform, which uses leading AI models to generate insights on diet, fitness, metabolism, brain function, and overall health.
• Availability: Kits are available for purchase this quarter on the Agenta Health e-commerce site.
• Data Privacy: The company has implemented specific safeguards to protect the privacy of sensitive genomic health data.

Notable Quotes

• "We believe consumers are looking for better information about their unique health situation to help guide their personal wellness plans," said Maryam Marissen, president and chief executive officer of Pangenomic Health. "The foundation of our NaraCare.AI platform is personalization, and there is no better baseline for that foundation than incorporating the unique genetic makeup of each individual."